Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.400
0.00 (0.00%)
Aug 8, 2025, 4:00 PM - Market closed
Accolade Stock Forecast
Stock Price Forecast
The 3 analysts that cover Accolade stock have a consensus rating of "Strong Buy" and an average price target of $5.67, which forecasts a 66.76% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $7.00.
Price Target: $5.67 (+66.76%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for Accolade stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +47.06% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +47.06% | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +47.06% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +47.06% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +47.06% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
6.38M
from 6.17M
Increased by 3.35%
Revenue Next Year
4.51M
from 6.38M
Decreased by -29.32%
EPS This Year
-0.27
from -0.38
EPS Next Year
-0.24
from -0.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 7.5M | 7.4M | 9.3M |
| Avg | 6.4M | 4.5M | 9.0M |
| Low | 4.5M | 2.7M | 8.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 20.8% | 16.2% | 105.7% |
| Avg | 3.4% | -29.3% | 99.8% |
| Low | -26.9% | -57.0% | 92.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.21 | -0.19 | -0.05 |
| Avg | -0.27 | -0.24 | -0.05 |
| Low | -0.31 | -0.28 | -0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.